|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 机械化学法制备的Al/Ce复合氧化物负载NiMo催化剂的加氢脱硫活性(英文)显示文摘将Al和/或Ce的硝酸盐与NH_4HCO_3球磨混合,采用机械化学法制备了Al_2O_3-CeO_2载体(其中Ce含量为1-10 wt%),再以杂多钼酸盐(NH_4)_4NiMo_6O_(24)为活性金属Ni和Mo的前驱体,通过浸渍法制备NiMo_6/Al_2O_3-CeO_2催化剂,并将其用于1-苯并噻吩(BT)的加氢脱硫(HDS)反应中.运用化学分析、X射线衍射、N_2吸附-脱附法、H_2程序升温还原、NH_3程序升温脱附和X射线光电子能谱对催化剂的物化性质进行了表征.结果表明,催化剂的酸性随着载体中Ce含量的增加而下降.Ce修饰的Al_2O_3载体表面的NiS/MoS原子比下降了2倍.NiMo_6/Al_2O_3催化剂表现出最高的HDS活性(以单位重量催化剂计),其酸性和表面MoO_xS_y物种的浓度(Mo^(5+)浓度)也最高;当催化剂中Ce含量逐渐增加到10 wt%以上时,其活性逐渐将为0.与浸渍法制得的参比催化剂相比,前驱体和催化剂组成相同的情况下,采用机械化学法制得的所有催化剂活性明显提高. | Květa Jirátová Alla Spojakina Luděk Kaluza Radostina Palcheva Jana Balabánová Georgi Tyuliev | 2016 | Chinese Journal of Catalysis2016，37，2： | 6 |
| 2 | 镍钼杂多酸制备NiMo/γ-Al_2O_3催化剂及硼、钴或镍改性氧化铝的影响(英文)显示文摘A hydrotreating NiMo/γ-Al2O3 catalyst(12 wt% Mo and 1.1 wt% Ni) was prepared by impregnation of the support with the Anderson-type heteropolyoxomolybdate(NH4)4Ni(OH)6Mo6O18.Before impregnation of the support,it was modified with an aqueous solution of H3BO3,Co(NO3)2,or Ni(NO3)2.The catalysts were investigated using N2 adsorption,O2 chemisorption,X-ray diffraction,UV-Vis spectroscopy,Fourier transform infrared spectroscopy,temperature-programmed reduction,temperature-programmed desorption,and X-ray photoelectron spectroscopy.The addition of Co,Ni,or B influenced the Al2O3 phase composition and gave increased catalytic activity for 1-benzothiophene hydrodesulfurization(HDS).X-ray photoelectron spectroscopy confirmed that the prior loading of Ni,Co or B increased the degree of sulfidation of the NiMo/γ-Al2O3 catalysts.The highest HDS activity was observed with the NiMo/γ-Al2O3 catalyst with prior loaded Ni. | Radostina PALCHEVA Luděk KALUZA Alla SPOJAKINA Květue JIRTOV Georgi TYULIEV | 2012 | 催化学报2012，33，6： | 6 |
| 3 | Supporting IrO2 and IrRuOx nanoparticles on TiO2 and Nb-doped TiO2 nanotubes as electrocatalysts for the oxygen evolution reaction显示文摘IrO2 and IrRuOx(Ir:Ru 60:40 at%),supported by 50 wt%onto titania nanotubes(TNTs)and(3 at%Nb)Nb-doped titania nanotubes(Nb-TNTs),as electrocatalysts for the oxygen evolution reaction(OER),were synthesized and characterized by means of structural,surface analytical and electrochemical techniques.Nb doping of titania significantly increased the surface area of the support from 145(TNTs)to 260 m2g-1(Nb-TNTs),which was significantly higher than those of the Nb-doped titania supports previously reported in the literature.The surface analytical techniques showed good dispersion of the catalysts onto the supports.The X-ray photoelectron spectroscopy analyses showed that Nb was mainly in the form of Nb(IV)species,the suitable form to behave as a donor introducing free electrons to the conduction band of titania.The redox transitions of the cyclic voltammograms,in agreement with the XPS results,were found to be reversible.Despite the supported materials presented bigger crystallite sizes than the unsupported ones,the total number of active sites of the former was also higher due to their better catalyst dispersion.Considering the outer and the total charges of the cyclic voltammograms in the range 0.1–1.4 V,stability and electrode potentials at given current densities,the preferred catalyst was Ir O2 supported on the Nb-TNTs.The electrode potentials corresponding to given current densities were between the smallest ones given in the literature despite the small oxide loading used in this work and its Nb doping,thus making the Nb-TNTs-supported IrO2 catalyst a promising candidate for the OER.The good dispersion of IrO2,high specific surface area of the Nb-doped supports,accessibility of the electroactive centers,increased stability due to Nb doping and electron donor properties of the Nb(IV)oxide species were considered the main reasons for its good performance. | Radostina V.Genova-Koleva Francisco Alcaide Garbine Alvarez Pere L.Cabot Hans-Jürgen Grande María V.Martínez-Huerta Oscar Miguel | 2019 | Journal of Energy Chemistry2019，28，7： | 2 |
| 4 | Inflammatory cytokines at admission—Independent prognostic markers in patients with acute coronary syndrome and hyperglycaemia显示文摘 | Zheyna Vlaeva Cherneva Stefan Veselinov Denchev Mariana Vasileva Gospodinova Adelina Cakova Radostina Vlaeva Cherneva | 2012 | Acute Cardiac Care2012，，1： | 1 |
| 5 | Incidence of zearalenone and fumonisins in Bulgarian cereal production 显示文摘 | Radostina Manova Rositsa Mladenova | 2009 | Food Control2009，，20： | 1 |
| 6 | Effect of the volume of fluids administered on intraoperative oliguria in laparoscopic bariatric surgery:a randomized controlled trial显示文摘 | Matot I Radostina P Eid L | 2012 | Arch Surg2012，147，3： | 1 |
| 7 | Genesis of filamentary pyrite associated with calcite crystals 显示文摘 | Bonev I K Juan Manmuel Garcia-Ruiz Radostina Atanassova | 2005 | Eur J Mineral2005，17，： | 1 |
| 8 | Mucosal COVID-19 vaccines:Risks,benefits and control of the pandemic显示文摘Based on mucosal immunization to promote both mucosal and systemic immune responses,next-generation coronavirus disease 2019(COVID-19)vaccines would be administered intranasally or orally.The goal of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)vaccines is to provide adequate immune protection and avoid severe disease and death.Mucosal vaccine candidates for COVID-19 including vector vaccines,recombinant subunit vaccines and live attenuated vaccines are under development.Furthermore,subunit protein vaccines and virus-vectored vaccines have made substantial progress in preclinical and clinical settings,resulting in SARS-CoV-2 intranasal vaccines based on the previously successfully used nasal vaccines.Additional to their ability to trigger stable,protective immune responses at the sites of pathogenic infection,the development of‘specific’mucosal vaccines targeting coronavirus antigens could be an excellent option for preventing future pandemics.However,their efficacy and safety should be confirmed. | Dimitrina Miteva Monika Peshevska-Sekulovska Violeta Snegarova Hristiana Batselova Radostina Alexandrova Tsvetelina Velikova | 2022 | World Journal of Virology2022，11，5： | 1 |
| 9 | Thiophene Hydrodesulfurization Aetivity of Alumina Supported Heteropoly Compounds: Nickel Effect显示文摘 | Radostina Palcheva Alia Spojakina Georgi Tyulied | 2006 | React Kinet Catal Lett2006，89，2： | 1 |
| 10 | Study of the nanosized Li 2 MnO 3 : Electrochemical behavior, structure, magnetic properties, and vibrational modes显示文摘 | S. Francis Amalraj Daniel Sharon Michael Talianker Christian M. Julien Luba Burlaka Ronit Lavi Ekaterina Zhecheva Boris Markovsky Ella Zinigrad Daniela Kovacheva Radostina Stoyanova Doron Aurbach | 2013 | Electrochimica Acta2013，，： | 1 |
| 11 | Layered solid solutions of LiNi1-XCoXO2 with α-LiGaO2 obtained under high oxygen pressure显示文摘 | Radostina Stoyanova Ekaterina Zhecheva Ricardo Alcantara | 2004 | J Mater Chem2004，14，： | 1 |
| 12 | Thiophene hydrodesulfurization activity of alumina supported heteropoly compounds: nickel effect显示文摘 | Radostina Palcheva Alla Spojakina* Georgi Tyuliev Kveta Jiratova Lachezar Petrov | 2006 | Reaction Kinetics and Catalysis Letters2006，，2： | 1 |
| 13 | Immunogenicity of recombinant hepatitis B vaccine in treatment-nave and treatment-experienced chronic hepatitis C patients: The effect of pegylated interferon plus ribavirin treatment显示文摘瞄准:为了回顾地评估导致种痘的 anti-HBs seroconversion,评价在处理天真并且处理富有经验长期的丙肝(CHC ) 病人。另外, seroconversion 加 ribavirin (肋骨) 在 pegylated 干扰素(木钉) 期间在 CHC 评估病人有希望地评估治疗。方法:七十个处理天真的 CHC 病人(组 A ) ,加肋骨治疗 CHC 病人(组 B ) 的 22 持续 virological responders-SVR 追随者干扰素(IFN ) 和 121 个健康题目(组 C ) 被参予了一样的 HBV 种痘时间表(20 microg, 0-1-6 瞬间) 。如果 anti-HBs 层次在在跟随疫苗的第三剂量的 3 瞬间以内的 10 mIU/mL 上面, Seroconversion 被考虑。而且,我们有希望地选择了 30 个非肝脏硬化症的 CHC 病人并且为使随机化的一样的疫苗的时间表的功效评估了他们他们在二个组:Group-1, 15 个 CHC 病人加肋骨治疗和 Group-2 与木钉的开始同时收到了疫苗的第一剂量,没有伴随物治疗, 15 个病人收到了一样的种痘时间表。anti-HBs 的决心在瞬间 1, 2,和 7 点被执行。数据的统计分析基于 ANOVA 学生的 t 测试和 chi 平方分析(P <
0.05 ) 。结果:70 个组 A 病人(82.85%) 中的 58 个, 20/22 组 B (90.9%) 和 112/121 健康题目(92.56%) 是 seroconverted。seroconversion 率比在处理天真的 CHC 病人在控制组是显著地更高的(P = 0.04 ) 。相应的率在组 A 和组 B CHC 病人之间是可比较的(P = 0.38 ) 。绝大多数非应答者(10/14, 71.43%) 被 HCV 的 genotype-1 感染了。seroconversion 率在在瞬间 1 点的组 1 和 2 CHC 病人之间是可比较的(20% 对 26.7% , P = 0.67 ) ,瞬间 2 (46.7% 对 60% , P = 0.46 ) 并且瞬间 7 (86.7% 对 93.3% , P = 0.54 ) 后续。结论:HBV 疫苗的 immunogenicity 似乎在与健康题目相比的 CHC 病人更低。SVR 后面的 IFN 正肋骨治疗不影响抗体反应到 HBV 疫苗。由 genotype-1 的感染似乎否定地影响 seroconversion 率。对 HBV 的种痘不以 anti-HBs seroconversion 率在加肋骨联合治疗的木钉期间是有益的。 | Ioannis S Elefsiniotis Elena Vezali Konstantinos Kamposioras Konstantinos D Pantazis Radostina Tontorova Ioannis Ketikoglou Antonios Moulakakis George Saroglou | 2006 | World Journal of Gastroenterology2006，12，27： | 0 |
| 14 | Synthesis, Spectral Properties, Antibacterial and Antitumor Activity of Salinomycin Complexes with the Transition Metal Ions Co(ll), Ni(ll), Cu(ll) and Zn(ll)显示文摘 | Juliana Ivanova Ivayla N. Pantcheva Rumyana Zhorova Georgi Momekov Svetlana Simova Radostina Stoyanova Ekaterina Zhecheva Simona Ivanova Mariana Mitewa | 2012 | Journal of Chemistry and Chemical Engineering2012，6，6： | 0 |
| 15 | Investigation on the Deformation of Functional Elements of Risky Technical Systems显示文摘 | Nikolay lvanov Petrov Radostina Vasileva Petrova | 2011 | Journal of Civil Engineering and Architecture2011，5，7： | 0 |
| 16 | Effectiveness and safety of COVID-19 vaccines in patients with oncological diseases:State-of-the-art显示文摘Although the coronavirus disease 2019(COVID-19)pandemic was declared to be no longer“a public health emergency of international concern”with its wide range of clinical manifestations and late complications,severe acute respiratory syndrome coronavirus 2 infection proved to be a serious threat,especially to the elderly and patients with comorbidities.Patients with oncologic diseases are vulnerable to severe infection and death.Indeed,patients with oncohematological diseases have a higher risk of severe COVID-19 and impaired post-vaccination immunity.Unfortunately,cancer patients are usually excluded from vaccine trials and investigations of post-vaccinal immune responses and the effectiveness of the vaccines.We aimed to elucidate to what extent patients with cancer are at increased risk of developing severe COVID-19 and what is their overall case fatality rate.We also present the current concept and evidence on the effectiveness and safety of COVID-19 vaccines,including boosters,in oncology patients.In conclusion,despite the considerably higher mortality in the cancer patient group than the general population,countries with high vaccination rates have demonstrated trends toward improved survival of cancer patients early and late in the pandemic. | Nedelcho Ivanov Boris Krastev Dimitrina Georgieva Miteva Hristiana Batselova Radostina Alexandrova Tsvetelina Velikova | 2023 | World Journal of Clinical Oncology2023，14，9： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员